Long-term Efficacy of Trilostane for Cushing's Syndrome due to Adrenocorticotropin-Independent Bilateral Macronodular Adrenocortical Hyperplasia

Yoshinari Obata, Yuya Yamada, Megu Yamaguchi Baden, Yoshiya Hosokawa, Kenji Saisho, Sachiko Tamba, Koji Yamamoto, Yuji Matsuzawa
2011 Internal medicine (Tokyo. 1992)  
A 66-year-old man with Cushing's syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia (AIMAH) was treated for 7 years with trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor. Administration of trilostane reduced the serum cortisol level to around the upper limit of normal for 7 years, and symptoms of excessive glucocorticoid production (such as moon face and obesity) were gradually improved. On the other hand, the size of both adrenal glands
more » ... ually increased despite treatment with trilostane. Though trilostane therapy could not prevent adrenal growth, it did suppress cortisol secretion over the long term, so it might be a reasonable option for AIMAH in addition to adrenalectomy.
doi:10.2169/internalmedicine.50.5578 pmid:22041369 fatcat:ntw2iirbzvc4lktdax2kvwat3e